Edivoxetine

Summary

Edivoxetine (CHEMBL2103857) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including major depressive disorder and attention deficit-hyperactivity disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 27
• Chemistry: 339.4 Da · C18H26FNO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2103857
Name	Edivoxetine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11186829
Molecular formula	C18H26FNO4
Molecular weight	339.4
InChIKey	CPBHSHYQQLFAPW-ZWKOTPCHSA-N

SMILES: COC1=C(C=C(C=C1)F)C[C@]([C@@H]2CNCCO2)(C3CCOCC3)O

IUPAC name: (1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(oxan-4-yl)ethanol

Also known as: Edivoxetina, Edivoxetine, LY-2216684, LY-2216684 HYDROCHLORIDE, LY2216684, EDIVOXETINE

Parent form; salt/anhydrous children: CHEMBL2105702

Patent coverage: 100 distinct patent families (265 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
major depressive disorder	3	MONDO:0002009	MONDO:0002009
attention deficit-hyperactivity disorder	2	MONDO:0007743	EFO:0003888

Clinical trials

Total trials: 27.

Phase distribution

Phase	Trials
PHASE1	16
PHASE3	6
PHASE2/PHASE3	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00795821	PHASE2/PHASE3	COMPLETED	A Study in Adult Patients With Major Depressive Disorder
NCT00922636	PHASE2/PHASE3	COMPLETED	A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder
NCT00965419	PHASE2/PHASE3	TERMINATED	A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
NCT01155661	PHASE3	COMPLETED	A Safety Study in Participants With Major Depressive Disorder
NCT01173601	PHASE3	COMPLETED	A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
NCT01185340	PHASE3	COMPLETED	A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
NCT01187407	PHASE3	COMPLETED	A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
NCT01299272	PHASE3	COMPLETED	A Study in Prevention of Re-emergence of Depression Symptoms
NCT01370499	PHASE3	COMPLETED	A Study of LY2216684 in Participants With Major Depression Disorder
NCT00420004	PHASE2	COMPLETED	A Study for Participants With Major Depression
NCT00840034	PHASE2	COMPLETED	A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
NCT01241435	PHASE1	COMPLETED	A Study of LY2216684 in Participants With Impaired Hepatic Function
NCT01243957	PHASE1	COMPLETED	A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
NCT01250873	PHASE1	COMPLETED	A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline
NCT01263093	PHASE1	COMPLETED	A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
NCT01263106	PHASE1	COMPLETED	A Study of LY2216684 and Theophylline in Healthy Subjects
NCT01263119	PHASE1	COMPLETED	A Study of LY2216684 and Warfarin in Healthy Subjects
NCT01263197	PHASE1	COMPLETED	A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol
NCT01263223	PHASE1	COMPLETED	A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors
NCT01266590	PHASE1	COMPLETED	A Study of LY2216684 and Digoxin in Healthy Subjects
NCT01275144	PHASE1	COMPLETED	A Study of the Effect of LY2216684 on Lorazepam
NCT01373931	PHASE1	COMPLETED	A Study of LY2216684 in Healthy Females
NCT01380691	PHASE1	COMPLETED	A Study of LY2216684 in Healthy Participants
NCT01389752	PHASE1	COMPLETED	A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
NCT01389765	PHASE1	COMPLETED	A Study to Evaluate the Effect of Food on LY2216684
NCT01460381	PHASE1	COMPLETED	A Study to Evaluate the Effect of Genotype on LY2216684
NCT01460407	PHASE1	COMPLETED	A Study to Evaluate the Effect of Clarithromycin on LY2216684

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).